<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fan, R.</style></author><author><style face="normal" font="default" size="100%">Papatheodoridis, G.</style></author><author><style face="normal" font="default" size="100%">Sun, J.</style></author><author><style face="normal" font="default" size="100%">Innes, H.</style></author><author><style face="normal" font="default" size="100%">Toyoda, H.</style></author><author><style face="normal" font="default" size="100%">Xie, Q.</style></author><author><style face="normal" font="default" size="100%">Mo, S.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Guha, I. N.</style></author><author><style face="normal" font="default" size="100%">Kumada, T.</style></author><author><style face="normal" font="default" size="100%">Niu, J.</style></author><author><style face="normal" font="default" size="100%">G Dalekos</style></author><author><style face="normal" font="default" size="100%">Yasuda, S.</style></author><author><style face="normal" font="default" size="100%">Barnes, E.</style></author><author><style face="normal" font="default" size="100%">Lian, J.</style></author><author><style face="normal" font="default" size="100%">Suri, V.</style></author><author><style face="normal" font="default" size="100%">Idilman, R.</style></author><author><style face="normal" font="default" size="100%">Barclay, S. T.</style></author><author><style face="normal" font="default" size="100%">Dou, X.</style></author><author><style face="normal" font="default" size="100%">Berg, T</style></author><author><style face="normal" font="default" size="100%">Hayes, P. C.</style></author><author><style face="normal" font="default" size="100%">Flaherty, J. F.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author><author><style face="normal" font="default" size="100%">Buti, M.</style></author><author><style face="normal" font="default" size="100%">Hutchinson, S. J.</style></author><author><style face="normal" font="default" size="100%">Guo, Y.</style></author><author><style face="normal" font="default" size="100%">Calleja, J. L.</style></author><author><style face="normal" font="default" size="100%">Lin, L.</style></author><author><style face="normal" font="default" size="100%">Zhao, L.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Janssen, H. L. A.</style></author><author><style face="normal" font="default" size="100%">Zhu, C.</style></author><author><style face="normal" font="default" size="100%">Shi, L.</style></author><author><style face="normal" font="default" size="100%">Tang, X.</style></author><author><style face="normal" font="default" size="100%">Gaggar, A.</style></author><author><style face="normal" font="default" size="100%">Wei, L.</style></author><author><style face="normal" font="default" size="100%">Jia, J.</style></author><author><style face="normal" font="default" size="100%">Irving, W. L.</style></author><author><style face="normal" font="default" size="100%">Johnson, P. J.</style></author><author><style face="normal" font="default" size="100%">Lampertico, P.</style></author><author><style face="normal" font="default" size="100%">Hou, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis</style></title><secondary-title><style face="normal" font="default" size="100%">J Hepatol</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/32707225</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;div id=&quot;enc-abstract&quot; class=&quot;abstract-content selected&quot;&gt;
&lt;p&gt;&lt;strong class=&quot;sub-title&quot;&gt; Background &amp;amp; aims: &lt;/strong&gt; Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.&lt;/p&gt;
&lt;p&gt;&lt;strong class=&quot;sub-title&quot;&gt; Methods: &lt;/strong&gt; A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686).&lt;/p&gt;
&lt;p&gt;&lt;strong class=&quot;sub-title&quot;&gt; Results: &lt;/strong&gt; We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin-bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82-0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7-100% and a negative predictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of 56.6-95.8% and a positive predictive value of 6.6-15.7%.&lt;/p&gt;
&lt;p&gt;&lt;strong class=&quot;sub-title&quot;&gt; Conclusions: &lt;/strong&gt; This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide.&lt;/p&gt;
&lt;p&gt;&lt;strong class=&quot;sub-title&quot;&gt; Lay summary: &lt;/strong&gt; In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin-bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity.&lt;/p&gt;
&lt;/div&gt;</style></abstract><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type></record></records></xml>